BeOne Medicines Ltd. (ONC) stock
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/301935% above fair value
$416.54+0.58 (+0.14%)
Close on Nov 13, 2026Market cap $47.36BP/E 53.4Yield –
BeOne Medicines gross margin
Gross margin is gross profit as a percentage of revenue.
BeOne Medicines's gross margin for the twelve months ending Sep 30, 2026 was 89.4%. For fiscal 2025 it was 87.5%, against 84.4% the year before. The highest annual figure on record is 100.0% in fiscal 2016.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 87.5% | +3.1 |
| FY2024 | Dec 31, 2024 | 84.4% | −0.1 |
| FY2023 | Dec 31, 2023 | 84.5% | +4.8 |
| FY2022 | Dec 31, 2022 | 79.8% | −6.2 |
| FY2021 | Dec 31, 2021 | 86.0% | +8.9 |
| FY2020 | Dec 31, 2020 | 77.1% | −6.3 |
| FY2019 | Dec 31, 2019 | 83.4% | −2.1 |
| FY2018 | Dec 31, 2018 | 85.5% | −12.4 |
| FY2017 | Dec 31, 2017 | 97.9% | −2.1 |
| FY2016 | Dec 31, 2016 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 88.5% | +2.4 |
| Q2 FY2026 | Jun 30, 2026 | 89.8% | +2.3 |
| Q1 FY2026 | Mar 31, 2026 | 89.0% | +3.7 |
| Q4 FY2025 | Dec 31, 2025 | 90.5% | +4.7 |
| Q3 FY2025 | Sep 30, 2025 | 86.1% | +3.1 |
| Q2 FY2025 | Jun 30, 2025 | 87.5% | +2.4 |
| Q1 FY2025 | Mar 31, 2025 | 85.2% | +1.9 |
| Q4 FY2024 | Dec 31, 2024 | 85.8% | +2.4 |
| Q3 FY2024 | Sep 30, 2024 | 83.0% | −4.7 |
| Q2 FY2024 | Jun 30, 2024 | 85.1% | +1.3 |
| Q1 FY2024 | Mar 31, 2024 | 83.4% | +1.6 |
| Q4 FY2023 | Dec 31, 2023 | 83.3% | +2.7 |
| Q3 FY2023 | Sep 30, 2023 | 87.7% | +7.4 |
| Q2 FY2023 | Jun 30, 2023 | 83.9% | +4.7 |
| Q1 FY2023 | Mar 31, 2023 | 81.7% | +3.0 |
| Q4 FY2022 | Dec 31, 2022 | 80.7% | +3.3 |
| Q3 FY2022 | Sep 30, 2022 | 80.3% | +3.2 |
| Q2 FY2022 | Jun 30, 2022 | 79.2% | +3.3 |
| Q1 FY2022 | Mar 31, 2022 | 78.7% | −15.9 |
| Q4 FY2021 | Dec 31, 2021 | 77.3% | −1.6 |
| Q3 FY2021 | Sep 30, 2021 | 77.0% | +0.2 |
| Q2 FY2021 | Jun 30, 2021 | 75.8% | −2.4 |
| Q1 FY2021 | Mar 31, 2021 | 94.6% | +21.8 |
| Q4 FY2020 | Dec 31, 2020 | 78.9% | +10.6 |
| Q3 FY2020 | Sep 30, 2020 | 76.8% | +16.9 |
| Q2 FY2020 | Jun 30, 2020 | 78.2% | −14.5 |
| Q1 FY2020 | Mar 31, 2020 | 72.8% | −7.6 |
| Q4 FY2019 | Dec 31, 2019 | 68.4% | −15.9 |
| Q3 FY2019 | Sep 30, 2019 | 59.9% | −24.0 |
| Q2 FY2019 | Jun 30, 2019 | 92.7% | +4.5 |
| Q1 FY2019 | Mar 31, 2019 | 80.4% | −5.6 |
| Q4 FY2018 | Dec 31, 2018 | 84.3% | +1.0 |
| Q3 FY2018 | Sep 30, 2018 | 83.9% | −15.2 |
| Q2 FY2018 | Jun 30, 2018 | 88.2% | – |
| Q1 FY2018 | Mar 31, 2018 | 86.0% | – |
| Q4 FY2017 | Dec 31, 2017 | 83.3% | – |
| Q3 FY2017 | Sep 30, 2017 | 99.1% | – |
See a number that looks wrong?